ClinicalTrials.gg
CompletedNCT02294682Updated May 23, 2017Results posted

A Dose-Ranging Study Evaluating the Efficacy, Safety, and Tolerability of GSK2140944 in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria Gonorrhoeae

A Phase 2 interventional study of GSK2140944 in Gonorrhea, sponsored by GlaxoSmithKline. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-23.

Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
106
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.

Enrollment
50th of 76
106 · median 341
Started
2015
with 3 others
Phase 2
11 of 98
none open now
Registered
40th of 98
by date

Among the 98 studies in Gonorrhea with a site in United States, this one is the 50th largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2015, is one of 11 in phase 2, and was the 40th registered.

Gonorrhea

168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.

Browse Gonorrhea studies →

Open to participants now

11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 98 studies in Gonorrhea with a site in United States, or all of them as a file.
02

Study summary

GSK2140944 has demonstrated in vitro activity against Neisseria (N.) gonorrhoeae, including ciprofloxacin resistant and susceptible strains. This study is a Phase II, randomized, multicenter, open-label, dose ranging study designed to inform the optimal oral dose of GSK2140944 by further characterizing the efficacy, safety, and tolerability in subjects with uncomplicated urogenital gonorrhea due to N. gonorrhoeae. Subjects will be randomly assigned to receive either a single 1500 milligrams (mg) or 3000 mg oral dose of GSK2140944. Appropriate safety and microbiological assessments will be conducted at the Baseline (Day 1) Visit and repeated at the Test-of-Cure (Day 4 to 8) Visit. The study duration will be approximately 1 week. Approximately 60 microbiologically evaluable subjects (30 subjects in each treatment arm) will complete the study if both arms remain active throughout the study.

03

Conditions studied

  • Gonorrhea

Browse trials for

Keywords

  • uncomplicated urogenital gonorrhea
  • Bacterial Type II Topoisomerase Inhibitors (BTI)
  • antibiotics
  • GSK2140944
  • N. gonorrhoeae
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is an adult male or female at least 18 years of age at the time of signing who meets one of the following criteria:

    1. A non-pregnant, non-lactating female of who 1) is sexually inactive by abstinence, 2) has a sole male partner who has been sterilized, or 3) uses a method with a failure rate of \<1% through the Test-of-Cure Visit. Females of childbearing potential must not become pregnant during the study.
    2. A female of non-childbearing potential, which includes the following: Females who are surgically sterile with a documented hysterectomy and/or bilateral oophorectomy; Females with documented tubal ligation. If the procedure was done hysteroscopically, the effectiveness of tubal occlusion must have been documented by hysterosalpingogram after the procedure (typically 3 months after the procedure); Females who are , defined as amenorrhoeic for greater than 1 year. For women whose menopausal status is in doubt, documented previous confirmatory blood samples with follicle-stimulating hormone >40 milli international units (mIU)/millilitre (mL) and estradiol \<40 picograms (pg)/mL (\<140 picomoles [pmol]/litre [L]) will need to be confirmed, or they will be required to use one of the acceptable contraception methods. Note: For the purposes of these criteria, "documented" includes information obtained via a verbal interview with the subject or from the subject's medical records.
  • There is clinical suspicion that the subject has a urogenital gonococcal infection (e.g., prior culture, nucleic acid amplification test [NAAT] or Gram stain presumptive or positive for the presence of N. gonorrhoeae, or sexual contact with a partner diagnosed with gonorrhea within the past 14 days, as reported by the subject). Note: All subjects will be tested for N. gonorrhoeae, but these results will not be used to determine subject eligibility for enrollment in the study.
  • The subject has provided written, dated, informed consent and is willing and able to comply with the study protocol.

Exclusion criteria

Exclusion Criteria:

  • The subject is pregnant or nursing.
  • The subject is a hysterectomized female without a cervix.
  • The subject is a male with a current diagnosis of epididymitis or orchitis at the time of the Baseline Visit.
  • The subject has a >=40.0 kilograms (kg)/square meter (m\^2).
  • The subject has a serious underlying disease that could be imminently life threatening, or the subject is unlikely to survive for the duration of the study period.
  • The subject has a medical condition or requires medication that may be aggravated by inhibition of acetylcholinesterase, such as: Poorly controlled asthma or at baseline and, in the opinion of the investigator, is not stable on current therapy; Acute severe pain, uncontrolled with conventional medical management; Active peptic ulcer disease; Parkinson's disease; Myasthenia gravis; A history of seizure disorder requiring medications for control. This does not include a history of childhood febrile seizures; Any evidence of mechanical obstruction of the urinary or digestive tracks.
  • The subject has had any past history or current diagnosis of Clostridium difficile infection at the time of the Baseline Visit.
  • The subject, in the judgment of the investigator, would not be able or willing to comply with the protocol or complete study follow-up.
  • The subject has a history of sensitivity to the study medication, or components thereof, or a history of a drug or other allergy that, in the opinion of the investigator or medical monitor, contraindicates their participation.
  • The subject has a PR interval \<120 or >220 milliseconds (msec). Note: Subjects without an evaluable PR interval (e.g., stable atrial fibrillation) are not eligible for this study.
  • The subject has a (QTc) >450 msec or a QTc >480 msec for subjects with bundle branch block. Note: The QTc is the QT interval corrected for heart rate according to either Bazett formula (QTcB), Fridericia formula (QTcF), machine, or manual overread.
  • The subject has QRS duration \<70 or >120 msec.
  • The subject has pre-existing Grade II atrioventricular block or higher or a history of significant vasovagal and/or syncopal episodes or episodes of symptomatic bradycardia.
  • The subject has a current or chronic history of liver disease (with the exception of Gilbert's syndrome), including symptomatic viral hepatitis and moderate to severe liver insufficiency ( class B or C).
  • The subject has been previously enrolled in this study or has previously been treated with GSK2140944.
  • The subject has participated in a clinical trial and has received an product within 30 days or 5 half-lives, whichever is longer.
  • The subject has the following gonococcal infections: Suspected or confirmed pelvic inflammatory disease; Suspected or confirmed gonococcal arthritis; Other evidence of disseminated gonococcal infection.
  • The subject has received treatment with a systemic or intravaginal antibacterial within 14 days of study entry.
  • Subject is taking a medication that has a known risk of torsades de pointes.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
106 participants (actual)

Study arms

  • Experimental
    GSK2140944 1500 mg

    Subjects will receive single oral dose of GSK2140944 1500 mg.

    Drug: GSK2140944

  • Experimental
    GSK2140944 3000 mg

    Subjects will receive single oral dose of GSK2140944 3000 mg.

    Drug: GSK2140944

Interventions

  • Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).

06

What researchers measure

Primary outcomes

  1. Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit

    Pre-treatment urogenital, pharyngeal, and rectal swab specimens were obtained for bacteriological culture for neisseria (N.) gonorrhoeae at the Baseline visit. Test- of-Cure was defined by infection site (that is urogenital and, as appropriate, rectal and/or pharyngeal) as culture confirmed bacterial eradication of N. gonorrhoeae observed 3 to 7 days post-treatment. Pre-treatment urogenital specimens were obtained for nucleic acid amplification test (NAAT) assay to detect the presence of N. gonorrhoeae and chlamydia trachomatis at the Baseline visit. Only participants who had a pre-therapy N. gonorrhoeae isolate recovered from their urogenital specimen were evaluated. Microbiologically evaluable (ME) Population comprised of all randomized participants who had N. gonorrhoeae isolated from Baseline cultures of urogenital swab specimens, received any dose of gepotidacin, and returned for their TOC visit.

    Time frame: Baseline (Day 1, pre-dose) and Test-of-Cure visit (Day 4 to 8)

Secondary outcomes

  1. Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

    An AE is any untoward medical occurrence in a clinical investigation participants, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia (defined as alanine aminotransferase \[ALT\] \>=3 times upper limit of normal \[ULN\] and bilirubin \>=2 times ULN \[\>35 percent direct\] \[or ALT \>=3 times ULN and international normalization ratio INR\>1.5, if INR is measured\].

    Time frame: From start of the study treatment until Test-of-Cure visit (Day 4 to 8)

  2. Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points

    BP was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8).Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit (Day 1) and Day 4 to Day 8

  3. Change From Baseline in Pulse Rate at the Indicated Time Points

    Pulse rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit (Day 1) and Day 4 to Day 8

  4. Change From Baseline in Temperature at the Indicated Time Points

    Temperature was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit (Day 1) and Day 4 to Day 8

  5. Change From Baseline in Respiratory Rate at the Indicated Time Points

    Respiratory rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements was obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC Visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit (Day 1) and Day 4 to Day 8

  6. Number of Participants With Abnormal Electrocardiogram (ECG) Findings

    A single 12-lead ECGs were obtained at the Baseline, 2 hour post-dose, and at the TOC (Day 4 to 8) visit using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. ECG was obtained prior to any vital sign measurements or blood draws scheduled on the same assessment day. For participants enrolled under protocol amendment 1, ECG was measured at Baseline visit Day 1 (pre-dose) only. ECG assessments were presented as abnormal-clinically significant (CS) and abnormal-not clinically significant (NCS) at the indicated time points. Only those participants available at the specified time points were analyzed (represented by n=X , X in the category titles).

    Time frame: Baseline visit and up to Day 8

  7. Number of Participants With Abnormal Physical Examination Finding

    Physical examination of respiratory, cardiovascular, abdomen, gastrointestinal, urogenital systems, pharyngeal and rectal examinations with collections of microbiology specimen was performed at the Baseline and TOC (Day 4 to 8) visit. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  8. Change From Baseline in Hemoglobin, Protein and Albumin at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hemoglobin, total protein and albumin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  9. Change From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hematocrit. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  10. Change From Baseline in Lymphocyte, Monocyte, Neutrophil Basophil, Eosinophil, Leukocyte and Platelet Count at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate neutrophil, lymphocyte, basophil, eosinophil, monocyte, leukocyte and platelet count. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  11. Change From Baseline in Bilirubin, Direct Bilirubin and Creatinine at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate bilirubin, direct bilirubin and creatinine. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  12. Change From Baseline in Alanine Aminotransferase, Aspartate Aminotransferase and Alkaline Phosphatase at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  13. Change From Baseline in Chloride, Calcium, Glucose, Potassium, Sodium and Urea at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate chloride, calcium, glucose, potassium, sodium and urea (blood urea nitrogen). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  14. Change From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes (red blood cell count). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  15. Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular hemoglobin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  16. Change From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8)

    Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular volume. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

  17. Number of Participants With Abnormal Urinalysis Dipstick Results

    Dipstick urinalysis was done for glucose, ketones, occult blood, protein, potential hydrogen (pH) and specific gravity at Baseline visit Day 1 (pre-dose) and Test-of-Cure visit (Day 4 to 8). Results were presented as negative (normal) or other findings reported only if observed under microscopic examination trace, 1+, 2+, 3+, 4+ and 5+ glucose, ketones, occult blood and protein. pH results were categorized as per their pH values. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

    Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)

07

Results

Posted May 23, 2017

Participant flow

This was a phase II, randomized, multicenter, open-label, dose ranging study evaluating the efficacy, safety and tolerability of gepotidacin therapy in participants with uncomplicated urogenital gonorrhea. The study duration was approximately 1 week with 2 planned study visits: Baseline (Day 1, pre-dose) and Test-of-Cure (TOC) (Day 4 to 8) visit.

Participant flow — Overall Study
MilestoneGSK2140944 1500 mgGSK2140944 3000 mg
Started5353
Completed5253
Not completed10
Withdrew: Could not swallow pills10

Outcome measures

PrimaryNumber of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit

Pre-treatment urogenital, pharyngeal, and rectal swab specimens were obtained for bacteriological culture for neisseria (N.) gonorrhoeae at the Baseline visit. Test- of-Cure was defined by infection site (that is urogenital and, as appropriate, rectal and/or pharyngeal) as culture confirmed bacterial eradication of N. gonorrhoeae observed 3 to 7 days post-treatment. Pre-treatment urogenital specimens were obtained for nucleic acid amplification test (NAAT) assay to detect the presence of N. gonorrhoeae and chlamydia trachomatis at the Baseline visit. Only participants who had a pre-therapy N. gonorrhoeae isolate recovered from their urogenital specimen were evaluated. Microbiologically evaluable (ME) Population comprised of all randomized participants who had N. gonorrhoeae isolated from Baseline cultures of urogenital swab specimens, received any dose of gepotidacin, and returned for their TOC visit.

Time frame:
Baseline (Day 1, pre-dose) and Test-of-Cure visit (Day 4 to 8)
Reported as:
Number · Participants
Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit
ParticipantsGSK2140944 1500 mgGSK2140944 3000 mg
Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit2937
Statistical analysis
  • GSK2140944 1500 mg · Microbio response urogenital gonorrhea: 97GSK2140944 1500 mg
  • GSK2140944 3000 mg · Microbio response urogenital gonorrhea: 95GSK2140944 3000 mg
SecondaryNumber of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)

An AE is any untoward medical occurrence in a clinical investigation participants, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia (defined as alanine aminotransferase \[ALT\] \>=3 times upper limit of normal \[ULN\] and bilirubin \>=2 times ULN \[\>35 percent direct\] \[or ALT \>=3 times ULN and international normalization ratio INR\>1.5, if INR is measured\].

Time frame:
From start of the study treatment until Test-of-Cure visit (Day 4 to 8)
Reported as:
Number · Participants
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
ParticipantsGSK2140944 1500 mgGSK2140944 3000 mg
Any AE2734
Any SAE00
SecondaryChange From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points

BP was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8).Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit (Day 1) and Day 4 to Day 8
Reported as:
Mean · Millimeter of mercury (mmHg)
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points
Millimeter of mercury (mmHg)GSK2140944 1500 mgGSK2140944 3000 mg
Systolic BP, Day 1, 2 hr post-dose, n=47, 480.4 ± 11.611.3 ± 11.97
Systolic BP, Day 4 to 8, n=52, 53-2.8 ± 13.110.5 ± 11.73
Diastolic BP, Day 1, 2 hr post-dose, n=47, 480.1 ± 7.61-0.9 ± 8.40
Diastolic BP, Day 4 to 8, n=52, 53-2.3 ± 8.73-2.2 ± 9.86
SecondaryChange From Baseline in Pulse Rate at the Indicated Time Points

Pulse rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit (Day 1) and Day 4 to Day 8
Reported as:
Mean · Beats per minute
Change From Baseline in Pulse Rate at the Indicated Time Points
Beats per minuteGSK2140944 1500 mgGSK2140944 3000 mg
Pulse rate Day 1, 2 hr post-dose, n=47, 48-0.3 ± 12.20-1.4 ± 8.72
Pulse rate, Day 4 to 8, n=52, 531.1 ± 11.922.2 ± 14.12
SecondaryChange From Baseline in Temperature at the Indicated Time Points

Temperature was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit (Day 1) and Day 4 to Day 8
Reported as:
Mean · Celsius
Change From Baseline in Temperature at the Indicated Time Points
CelsiusGSK2140944 1500 mgGSK2140944 3000 mg
Temperature, Day 1, 2 hr post-dose, n=47, 48-0.126 ± 0.4327-0.052 ± 0.3664
Temperature, Day 4 to 8, n=52, 53-0.121 ± 0.4953-0.088 ± 0.3742
SecondaryChange From Baseline in Respiratory Rate at the Indicated Time Points

Respiratory rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements was obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC Visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit (Day 1) and Day 4 to Day 8
Reported as:
Mean · Breaths per minute
Change From Baseline in Respiratory Rate at the Indicated Time Points
Breaths per minuteGSK2140944 1500 mgGSK2140944 3000 mg
Respiratory rate, Day 1, 2 hr post-dose, n=47, 48-0.1 ± 1.39-0.3 ± 1.51
Respiratory rate, Day 4 to 8, n=52, 530.1 ± 1.66-0.1 ± 1.61
SecondaryNumber of Participants With Abnormal Electrocardiogram (ECG) Findings

A single 12-lead ECGs were obtained at the Baseline, 2 hour post-dose, and at the TOC (Day 4 to 8) visit using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. ECG was obtained prior to any vital sign measurements or blood draws scheduled on the same assessment day. For participants enrolled under protocol amendment 1, ECG was measured at Baseline visit Day 1 (pre-dose) only. ECG assessments were presented as abnormal-clinically significant (CS) and abnormal-not clinically significant (NCS) at the indicated time points. Only those participants available at the specified time points were analyzed (represented by n=X , X in the category titles).

Time frame:
Baseline visit and up to Day 8
Reported as:
Number · Participants
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
ParticipantsGSK2140944 1500 mgGSK2140944 3000 mg
Abnormal-NCS, pre-dose Day 1, n=52, 531412
Abnormal-CS, pre-dose Day 1, n=52, 5300
Abnormal-NCS, Day 1, 2 hr post, n=37, 3689
Abnormal-CS, Day 1, 2 hr post, n=37, 3600
Abnormal-NCS, Day 4 to 8, n=37, 35711
Abnormal-CS, Day 4 to 8, n=37, 3500
SecondaryNumber of Participants With Abnormal Physical Examination Finding

Physical examination of respiratory, cardiovascular, abdomen, gastrointestinal, urogenital systems, pharyngeal and rectal examinations with collections of microbiology specimen was performed at the Baseline and TOC (Day 4 to 8) visit. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Number · Participants
Number of Participants With Abnormal Physical Examination Finding
ParticipantsGSK2140944 1500 mgGSK2140944 3000 mg
Abdomen, Baseline, n=50, 5320
Abdomen, TOC, n=51, 5200
Cardiovascular, Baseline, n=52, 5311
Cardiovascular, TOC, n=51, 5300
Gastrointestinal, Baseline, n=49, 5210
Gastrointestinal, TOC, n=50, 5120
Pharyngeal, Baseline, n=51, 5114
Pharyngeal, TOC, n=51, 5200
Rectal examination, Baseline, n=46, 4624
Rectal examination, TOC, n=41, 4212
Respiratory, Baseline, n=52, 5310
Respiratory, TOC, n=52, 5300
Urogenital, Baseline, n=52, 534947
Urogenital, TOC, n=52, 5156
SecondaryChange From Baseline in Hemoglobin, Protein and Albumin at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hemoglobin, total protein and albumin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Gram (G)/Liter (L)
Change From Baseline in Hemoglobin, Protein and Albumin at Test-of-Cure Visit (Day 4 to 8)
Gram (G)/Liter (L)GSK2140944 1500 mgGSK2140944 3000 mg
Hemoglobin, n=46, 53-3.0 ± 6.89-3.9 ± 8.79
Albumin, n=52, 53-0.5 ± 2.10-0.8 ± 2.51
Protein, n=52, 53-1.1 ± 3.62-2.0 ± 4.01
SecondaryChange From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hematocrit. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Proportion of blood
Change From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8)
Proportion of bloodGSK2140944 1500 mgGSK2140944 3000 mg
Change From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8)-0.0117 ± 0.02213-0.0155 ± 0.03166
SecondaryChange From Baseline in Lymphocyte, Monocyte, Neutrophil Basophil, Eosinophil, Leukocyte and Platelet Count at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate neutrophil, lymphocyte, basophil, eosinophil, monocyte, leukocyte and platelet count. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · 10^9 cells/L
Change From Baseline in Lymphocyte, Monocyte, Neutrophil Basophil, Eosinophil, Leukocyte and Platelet Count at Test-of-Cure Visit (Day 4 to 8)
10^9 cells/LGSK2140944 1500 mgGSK2140944 3000 mg
Lymphocytes, n=46, 520.141 ± 0.54370.053 ± 0.6846
Monocytes, n=46, 52-0.013 ± 0.13390.026 ± 0.1377
Neutrophils , n=46, 52-0.834 ± 1.7564-0.598 ± 1.9185
Platelets, n=45, 536.4 ± 35.63-5.8 ± 26.41
Basophils, n=46, 52-0.001 ± 0.01460.002 ± 0.0155
Eosinophils, n=46, 520.023 ± 0.11470.027 ± 0.1187
Leukocytes, n=46, 52-0.69 ± 1.692-0.49 ± 1.947
SecondaryChange From Baseline in Bilirubin, Direct Bilirubin and Creatinine at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate bilirubin, direct bilirubin and creatinine. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Micromole (UMOL)/ L
Change From Baseline in Bilirubin, Direct Bilirubin and Creatinine at Test-of-Cure Visit (Day 4 to 8)
Micromole (UMOL)/ LGSK2140944 1500 mgGSK2140944 3000 mg
Bilirubin, n=52, 53-1.4 ± 5.420.4 ± 4.01
Direct bilirubin, n=52, 53-0.2 ± 1.110.2 ± 1.45
Creatinine, n=52, 531.38 ± 9.9892.01 ± 7.737
SecondaryChange From Baseline in Alanine Aminotransferase, Aspartate Aminotransferase and Alkaline Phosphatase at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · International units (IU)/ L
Change From Baseline in Alanine Aminotransferase, Aspartate Aminotransferase and Alkaline Phosphatase at Test-of-Cure Visit (Day 4 to 8)
International units (IU)/ LGSK2140944 1500 mgGSK2140944 3000 mg
Alanine Aminotransferase, n=52, 531.2 ± 7.241.8 ± 8.41
Aspartate Aminotransferase, n=52, 532.0 ± 7.692.5 ± 8.69
Alkaline Phosphatase, n=52, 53-1.8 ± 6.73-2.2 ± 6.26
SecondaryChange From Baseline in Chloride, Calcium, Glucose, Potassium, Sodium and Urea at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate chloride, calcium, glucose, potassium, sodium and urea (blood urea nitrogen). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Millimole (MMOL)/L
Change From Baseline in Chloride, Calcium, Glucose, Potassium, Sodium and Urea at Test-of-Cure Visit (Day 4 to 8)
Millimole (MMOL)/LGSK2140944 1500 mgGSK2140944 3000 mg
Chloride, n=52, 530.7 ± 2.020.3 ± 1.92
Calcium, n=52, 53-0.017 ± 0.0869-0.047 ± 0.0874
Glucose, n=52, 53-0.18 ± 1.184-0.02 ± 0.959
Potassium, n=52, 530.04 ± 0.359-0.01 ± 0.355
Sodium, n=52, 530.1 ± 2.28-0.1 ± 1.95
Urea, n=52, 530.07 ± 1.0980.04 ± 1.228
SecondaryChange From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes (red blood cell count). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · 10^12/L
Change From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8)
10^12/LGSK2140944 1500 mgGSK2140944 3000 mg
Change From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8)-0.10 ± 0.227-0.15 ± 0.338
SecondaryChange From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular hemoglobin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Picograms
Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8)
PicogramsGSK2140944 1500 mgGSK2140944 3000 mg
Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8)0.08 ± 0.4570.12 ± 0.461
SecondaryChange From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8)

Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular volume. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Mean · Femtoliters
Change From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8)
FemtolitersGSK2140944 1500 mgGSK2140944 3000 mg
Change From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8)-0.3 ± 1.85-0.2 ± 1.71
SecondaryNumber of Participants With Abnormal Urinalysis Dipstick Results

Dipstick urinalysis was done for glucose, ketones, occult blood, protein, potential hydrogen (pH) and specific gravity at Baseline visit Day 1 (pre-dose) and Test-of-Cure visit (Day 4 to 8). Results were presented as negative (normal) or other findings reported only if observed under microscopic examination trace, 1+, 2+, 3+, 4+ and 5+ glucose, ketones, occult blood and protein. pH results were categorized as per their pH values. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).

Time frame:
Baseline visit and Test-of-Cure visit (Day 4 to 8)
Reported as:
Number · Participants
Number of Participants With Abnormal Urinalysis Dipstick Results
ParticipantsGSK2140944 1500 mgGSK2140944 3000 mg
Glucose, pre-dose, Day 1, negative, n=50, 534853
Glucose, pre-dose, Day 1, trace, n=50, 5310
Glucose, pre-dose, Day 1, 1+, n=50, 5300
Glucose, pre-dose, Day 1, 2+, n=50, 5300
Glucose, pre-dose, Day 1, 3+, n=50, 5310
Glucose, pre-dose, Day 1, 4+, n=50, 5300
Glucose, pre-dose, Day 1, 5+, n=50, 5300
Glucose, Day 4 to 8, negative, n=48, 534753
Glucose, Day 4 to 8, trace, n=48, 5300
Glucose, Day 4 to 8, 1+, n=48, 5300
Glucose, Day 4 to 8, 2+, n=48, 5300
Glucose, Day 4 to 8, 3+, n=48, 5310
Glucose, Day 4 to 8, 4+, n=48, 5300
Glucose, Day 4 to 8, 5+, n=48, 5300
Ketones, pre-dose, Day 1, negative, n=50, 534849
Ketones, pre-dose, Day 1, trace, n=50, 5323
Ketones, pre-dose, Day 1, 1+, n=50, 5301
Ketones, pre-dose, Day 1, 2+, n=50, 5300
Ketones, pre-dose, Day 1, 3+, n=50, 5300
Ketones, pre-dose, Day 1, 4+, n=50, 5300
Ketones, pre-dose, Day 1, 5+, n=50, 5300
Ketones, Day 4 to 8, negative, n=48, 534548
Ketones, Day 4 to 8, trace, n=48, 5334
Ketones, Day 4 to 8, 1+, n=48, 5301
Ketones, Day 4 to 8, 2+, n=48, 5300
Ketones, Day 4 to 8, 3+, n=48, 5300
Ketones, Day 4 to 8, 4+, n=48, 5300
Ketones, Day 4 to 8, 5+, n=48, 5300
Occult blood, pre-dose, Day 1, negative, n=50, 533542
Occult blood, pre-dose, Day 1, trace, n=50, 5364
Occult blood, pre-dose, Day 1, 1+, n=50, 5367
Occult blood, pre-dose, Day 1, 2+, n=50, 5320
Occult blood, pre-dose, Day 1, 3+, n=50, 5310
Occult blood, pre-dose, Day 1, 4+, n=50, 5300
Occult blood, pre-dose, Day 1, 5+, n=50, 5300
Occult blood, Day 4 to 8, negative, n=48, 534549
Occult blood, Day 4 to 8, trace, n=48, 5300
Occult blood, Day 4 to 8, 1+, n=48, 5311
Occult blood, Day 4 to 8, 2+, n=48, 5320
Occult blood, Day 4 to 8, 3+, n=48, 5303
Occult blood, Day 4 to 8, 4+, n=48, 5300
Occult blood, Day 4 to 8, 5+, n=48, 5300
Protein, pre-dose, Day 1, negative, n=50, 533739
Protein, pre-dose, Day 1, trace, n=50, 5389
Protein, pre-dose, Day 1, 1+, n=50, 5345
Protein, pre-dose, Day 1, 2+, n=50, 5310
Protein, pre-dose, Day 1, 3+, n=50, 5300
Protein, pre-dose, Day 1, 4+, n=50, 5300
Protein, pre-dose, Day 1, 5+, n=50, 5300
Protein, Day 4 to 8, negative, n=48, 534243
Protein, Day 4 to 8, trace, n=48, 5347
Protein, Day 4 to 8, 1+, n=48, 5322
Protein, Day 4 to 8, 2+, n=48, 5301
Protein, Day 4 to 8, 3+, n=48, 5300
Protein, Day 4 to 8, 4+, n=48, 5300
Protein, Day 4 to 8, 5+, n=48, 5300
pH, pre-dose, Day 1, pH 5, n=50, 5321
pH, pre-dose, Day 1, pH 5.5, n=50, 5358
pH, pre-dose, Day 1, pH 6, n=50, 53138
pH, pre-dose, Day 1, pH 6.5, n=50, 531214
pH, pre-dose, Day 1, pH 7, n=50, 531214
pH, pre-dose, Day 1,pH 7.5 ,n=50, 5347
pH, pre-dose, Day 1, pH 8, n=50, 5321
pH, Day 4 to 8, pH 5, n=48, 5300
pH, Day 4 to 8, pH 5.5, n=48, 531011
pH, Day 4 to 8, pH 6, n=48, 531315
pH, Day 4 to 8, pH 6.5, n=48, 53914
pH, Day 4 to 8, pH 7, n=48, 53107
pH, Day 4 to 8, pH 7.5, n=48, 5353
pH, Day 4 to 8, pH 8, n=48, 5313

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of the study treatment (Day1) until Test-of-Cure visit (Day 4 to 8).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GSK2140944 1500 mg—0/52 (0%)22/52 (42.3%)
GSK2140944 3000 mg—0/53 (0%)28/53 (52.8%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventGSK2140944 1500 mgGSK2140944 3000 mg
DiarrhoeaGastrointestinal disorders9/5219/53
FlatulenceGastrointestinal disorders14/5210/53
NauseaGastrointestinal disorders3/5211/53
Abdominal painGastrointestinal disorders6/5210/53
DizzinessNervous system disorders1/526/53
HyperhidrosisSkin and subcutaneous tissue disorders1/526/53
FatigueGeneral disorders3/525/53
Abdominal discomfortGastrointestinal disorders4/522/53
Feeling hotGeneral disorders1/524/53
EructationGastrointestinal disorders1/523/53

Baseline characteristics

Age, Continuous
Age, Continuous(Years)GSK2140944 1500 mgGSK2140944 3000 mgTotal
Mean34.1 ± 11.4532.4 ± 11.3333.3 ± 11.37
Sex: Female, Male
Sex: Female, Male(Participants)GSK2140944 1500 mgGSK2140944 3000 mgTotal
Female325
Male5051101
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)GSK2140944 1500 mgGSK2140944 3000 mgTotal
African American/African Heritage (Heri.)222547
American Indian or Alaska Native112
Central/South Asian Heritage011
Japanese/East Asian Heri. /South East Asian Heri.101
Native Hawaiian or other Pacific Islander011
White242145
White & African American/African Heritage011
Unknown538
08

Study locations

14 sites
  • GSK Investigational Site
    Fountain Valley, California 92708, United States
  • GSK Investigational Site
    Los Angeles, California 90028, United States
  • GSK Investigational Site
    Los Angeles, California 90069, United States
  • GSK Investigational Site
    Palm Springs, California 92262, United States
  • GSK Investigational Site
    San Francisco, California 94103, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Atlanta, Georgia 30308, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    New Orleans, Louisiana 70119, United States
  • GSK Investigational Site
    Omaha, Nebraska 68114, United States
  • GSK Investigational Site
    Cleveland, Ohio 44109, United States
  • GSK Investigational Site
    Jenkintown, Pennsylvania 19046, United States
  • GSK Investigational Site
    San Juan, 00927, Puerto Rico
  • GSK Investigational Site
    London, SW10 9NH, United Kingdom
09

References and documents

Publications

  • Scangarella-Oman NE, Hossain M, Dixon PB, Ingraham K, Min S, Tiffany CA, Perry CR, Raychaudhuri A, Dumont EF, Huang J, Hook EW 3rd, Miller LA. Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae. Antimicrob Agents Chemother. 2018 Nov 26;62(12):e01221-18. doi: 10.1128/AAC.01221-18. Print 2018 Dec. PubMed 30249694 ↗
  • Taylor SN, Morris DH, Avery AK, Workowski KA, Batteiger BE, Tiffany CA, Perry CR, Raychaudhuri A, Scangarella-Oman NE, Hossain M, Dumont EF. Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation. Clin Infect Dis. 2018 Aug 1;67(4):504-512. doi: 10.1093/cid/ciy145. PubMed 29617982 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.

Results were first posted in May 2017, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 17, 2014
First posted
Nov 19, 2014
Start
Apr 15, 2015
Primary completionActual
Jul 1, 2016
CompletionActual
Jul 27, 2016
Results first posted
May 23, 2017
Last update
May 23, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 23, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02294682
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Nov 19, 2014
Start date
Apr 15, 2015
Primary completion
Jul 1, 2016
Completion
Jul 27, 2016
Results posted
May 23, 2017
Last update
May 23, 2017

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Gepotidacin

Start the discussion